Company: STAA
Filing Date: 2025-12-09
Form Type: DFAN14A
Source: 0001104659-25-119511
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-12-09
Form: DFAN14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934</div>

| Filed by the Registrant  ☐ |     | Filed by a party other than the Registrant x |

Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |

| ☐ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| x | Soliciting Material Pursuant to §240.14a-12 |

<div align='center'>Staar Surgical Company

(Name of Registrant as Specified In Its Charter)

Alcon Inc.

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

| x | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

Alcon released the following press release and investor discussion materials on December 9, 2025 related to the proposed acquisition of STAAR Surgical Company.

Alcon Announces Amended Merger Agreement with STAAR Surgical

| · | Agreement                                                                        
 follows discussions with STAAR stockholders and the closure of STAAR’s “go-shop” 
 period                                                                           |

| · | New                                                                                     
 terms include an increase in acquisition price and reductions in payments to executives |

GENEVA, Switzerland, Dec 9, 2025 –Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an amended merger agreement for the acquisition of STAAR Surgical Company (NASDAQ: STAA, “STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) forvision correction.

In November 2025, by mutual agreement with Alcon, the STAAR Board began an unencumbered “go-shop” process, in connection with which Alcon waived its matching rights and any break-up fee if a superior proposal